What is Zacks Research’s Estimate for TMO Q2 Earnings?

Thermo Fisher Scientific Inc. (NYSE:TMO) – Research analysts at Zacks Research cut their Q2 2025 earnings estimates for Thermo Fisher Scientific in a note issued to investors on Wednesday, May 14th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $5.22 per share for the quarter, down from their prior estimate of $5.59. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific’s Q3 2025 earnings at $5.53 EPS, FY2025 earnings at $22.32 EPS and Q1 2027 earnings at $6.94 EPS.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the previous year, the firm posted $5.11 earnings per share. The company’s revenue was up .2% on a year-over-year basis.

Several other equities research analysts have also recently commented on the stock. The Goldman Sachs Group set a $610.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Wednesday, April 23rd. Raymond James reiterated an “outperform” rating and set a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, April 24th. Finally, StockNews.com cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Friday, April 25th. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $607.43.

Thermo Fisher Scientific Stock Down 0.4%

Shares of NYSE:TMO opened at $404.27 on Friday. Thermo Fisher Scientific has a one year low of $390.50 and a one year high of $627.88. The company has a 50 day moving average of $455.92 and a 200-day moving average of $511.36. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock has a market cap of $152.61 billion, a price-to-earnings ratio of 24.46, a P/E/G ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were given a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.43%. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.09%.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares of the company’s stock, valued at approximately $5,759,736.32. This trade represents a 25.87% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Belmont Capital LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at approximately $249,000. Alliancebernstein L.P. increased its stake in Thermo Fisher Scientific by 18.3% during the 1st quarter. Alliancebernstein L.P. now owns 1,766,067 shares of the medical research company’s stock valued at $878,795,000 after purchasing an additional 272,747 shares in the last quarter. Advisors Asset Management Inc. increased its stake in Thermo Fisher Scientific by 2.0% during the 1st quarter. Advisors Asset Management Inc. now owns 21,031 shares of the medical research company’s stock valued at $10,465,000 after purchasing an additional 419 shares in the last quarter. Amundi boosted its holdings in Thermo Fisher Scientific by 5.9% during the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock worth $1,426,316,000 after acquiring an additional 168,197 shares during the last quarter. Finally, Aprio Wealth Management LLC boosted its holdings in Thermo Fisher Scientific by 52.7% during the 1st quarter. Aprio Wealth Management LLC now owns 1,561 shares of the medical research company’s stock worth $777,000 after acquiring an additional 539 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.